A closer look at “FTC and States Seek Contempt Ruling Against Martin Shkreli for Violating Lifetime Pharma B”, exactly as the source publishes it. The Federal Trade Commission and attorneys general from seven states have asked a federal judge to hold Martin Shkreli in contempt, alleging he 'flagrantly and repeatedly' violated a lifetime ban from the pharmaceutical industry. The ban was imposed in 2022 after Shkreli, known for hiking the price of Daraprim by over 5,000%, was found liable for anticompetitive conduct. The FTC and states now claim Shkreli has continued to engage in drug-related activities through new ventures, including a company called Druglike, which they say operates in defiance of the court order.
The motion argues that Shkreli's actions undermine the original ruling and harm consumers. If found in contempt, Shkreli could face significant penalties, including fines and possible imprisonment. This listing links straight to the original page, where the content is available in full.